Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WOMEN&More: Mifepristone 50 mg Once-weekly as a Contraceptive
NCT06394999Phase 3Active, not recruiting
- Sponsor
- Leiden University Medical Center
- Start
- May 2025
- Primary completion
- Jun 2027
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of mifepristone in contraception, sponsored by Leiden University Medical Center. Primary endpoints: Overall Pearl Index at 12 months, Pearl Index by Method failure at 12 months and 1 more. Started May 2025; status: active, not recruiting.
02
Drugs
mifepristone
03
Conditions
contraception
Beyond the preview
Go deeper on NCT06394999.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06394999.